Each ml of Brimo 0.2% eye drops contains:
Active substance: Brimonidine Tartrate BP 2 mg.
Preservative: Benzalkonium Chloride 0.05 mg.
Brimo is a sterile eye drops containing Brimonidine Tartrate, a selective alpha-2 adrenergic receptor agonist for topical administration into the eyes.
Mode of Action:
Brimonidine is an alpha-2 adrenoreceptor agonist that is more selective for the alpha-2 adrenoreceptor than alpha-1. Topical administration of Brimonidine Tartrate eye drops decreases intraocular pressure (IOP) in humans. When used as directed, Brimonidine Tartrate have the action of reducing elevated IOP with minimal effect on cardiovascular parameters. Brimonidine Tartrate eye drops have a rapid onset of action with the peak ocular hypotensive effect occurring at two hours post-dosing. The duration of effect is 12 hours or greater. Fluorophotometric studies in animals and humans suggest that Brimonidine Tartrate has a dual mechanism of action. Brimonidine Tartrate eye drops lower IOP by reducing aqueous humor production and enhancing uveoscleral outflow.
Brimo sterile eye drops is effective for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
The recommended dose is one drop in the affected eye(s) two times daily.
Brimo may be used concomitantly with other topical ophthalmic drugs to lower intraocular pressure. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.
*Prescription only*
Although specific drug interaction studies have not been conducted with Brimonidine Tartrate eye drops, the possibility of an additive effect with CNS depressants (alcohol, barbiturates, opiates, sedatives or anesthetics) should be considered.
Overdose:
No information is available on overdose in humans. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained. In the event of a topical overdose, flush eye with a topical ocular irrigant.
There are no studies of Brimonidine Tartrate eye drops in pregnant women, however in animal studies, Brimonidine Tartrate crossed the placenta and entered into the fetal circulation to a related extent. Brimonidine Tartrate eye drops should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
It is not known whether Brimonidine Tartrate is excreted in human milk, although in animal studies, Brimonidine Tartrate has been shown to be excreted in breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Although Brimonidine Tartrate had minimal effects on blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. It has not been studied in patients with hepatic or renal impairment; caution should be used in treating such patients.
Store at below 30°C in a dry place protected from light and freezing. Do not touch dropper tip to any surface. It is desirable that the contents should not be used more than one month after first opening of the bottle.